GE Healthcare announces agreement to acquire interventional guidance innovator Imactis

799

GE healthcareGE Healthcare announced it has entered into an agreement to acquire Imactis, an innovator in computed tomography (CT) interventional guidance across an array of care areas. Imactis is a France-based company that was founded in 2009 by Stéphane Lavallée and Lionel Carrat, who created CT-Navigation, an ergonomic universal solution that provides stereotactic needle guidance, enabling intuitive pre-planning and continuous control throughout a wide range of procedures, from diagnosis to treatment.

“We are thrilled to take this step in strengthening our interventional guidance offering for patients and customers,” said Jan Makela, president and CEO of imaging, GE Healthcare. “The Imactis CT-Navigation system is designed to improve workflow for interventional radiologists and hospitals by increasing procedural accuracy, while helping to reduce procedure time and radiation dose for patients and physicians. It is an innovative navigation solution for image-guided percutaneous procedures that aims for better patient outcomes, by reducing variability for simple and complex procedures and improving reproducibility.”

“The timing to join GE Healthcare is perfect,” said Pierre Olivier, president and CEO of Imactis. “Our solution, which is already deployed in leading healthcare systems in Europe and the USA, is ready to scale and become a standard of care, thanks to GE Healthcare’s market access. Our product development team also sees significant opportunities to integrate our hardware and software into GE Healthcare solutions and make the workflow of the interventional radiologists and oncologists even simpler and faster.”

While this innovation currently focuses on CT, GE Healthcare plans to expand the technology to its image-guided therapy (IGT) business to drive further growth.

The Imactis CT-Navigation, which includes an integrated workstation, guidance software, and disposable procedure kit, is currently approved under the European Union’s Medical Devices Regulation (MDR) and has US Food and Drug Administration (FDA) clearance for use within the USA.

The consummation of the transaction is subject to customary closing conditions, including review by the relevant governmental authorities in France. Financial details of the transaction have not been disclosed publicly.


LEAVE A REPLY

Please enter your comment!
Please enter your name here